Genentech takes the health and safety of our patients, customers, employees and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page or call 1-877-436-3683.

Margaret Porter Scott - Vice President, Biochemical & Cellular Pharmacology

Margaret Porter Scott

Vice President, Biochemical & Cellular Pharmacology

"Discovering and developing the next generation of therapeutics will not be easy – and that’s what motivates me."
Years at Genentech
Awards & Honors

I joined Genentech because great science with great people is what I want do. I have spent my career seeking the best ways to “reduce to practice” the key aspects of highly complex disease biology so that new drug discovery programs can be initiated and progressed. This leads to a tight partnership with Disease Biology and I count myself so fortunate to have a role in Biochemical and Cellular Pharmacology focusing on the portfolio of cancer targets in partnership with the world-class Oncology Biology team here at Genentech.


Featured Publication

Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Proc Nat. Acad Sci. 2010 107(49):20980-5.

Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA.